Celldex Therapeutics Inc (CLDX NASDAQ) stock market data APIs
$30.9968
-0.13(-0.4%)
as of May 22, 2026
Try our APIs with
free plan!
Celldex Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Prev. Close
30.9968
Open
30.8643
High
31.4994
Low
30.8062
52 wk Range
18.55-35.79
Market Cap
2 412 M
Shares Outstanding
78 492 K
Revenue
865 K
EPS
-1.18
Beta
0.982
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Celldex Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Celldex Therapeutics Inc data using free add-ons & libraries
Get Celldex Therapeutics Inc Fundamental Data
Celldex Therapeutics Inc Fundamental data includes:
- Net Revenue: 865 K
- EBITDA: -305 696 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Celldex Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-05-08
- EPS/Forecast: -1.1322
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Celldex Therapeutics Inc News
![[Latest] Global Cholera Vaccine Market Size/Share Worth USD 649 Million by 2035 at a 7.6 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)](/build/assets/fallback7-edDikJRC.jpg)
New
[Latest] Global Cholera Vaccine Market Size/Share Worth USD 649 Million by 2035 at a 7.6 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Cholera Vaccine Market size & share revenue wa...
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed Signals
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Celldex Therapeutics stock overview Celldex Therapeutics (CLDX) has been drawi...
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $0.81 per share a year ago. These figure...
Celldex Reports First Quarter Financial Results and Provides Corporate Update
Celldex Therapeutics, Inc. Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; ...
Get Celldex Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
